These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. The first two numbers are 12 and 19. As a result, it's popular with a wide variety of employers. Upon any work, and especially upon a play, a great . | Find, read and cite all the research you . 2 answers. I submitted a resume and was invited to take their abstractor assessment. Less than 1% of people complete all 50 questions. Our admissions process includes three phases a written application, the admissions test, and an admissions interview. New York, NY 10004 Sorry, this job was removed at 11:18 a.m. (CST) on Friday, December 9, 2022, Find out whos hiring remotely Nationwide, By clicking continue you agree to Built Ins. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail I fundamentally believe in the mission of Flatiron and what we are trying to accomplish with our software and we still have a lot of work to do to continue transforming oncology care. Michigan Oncology Quality Consortium * Hospital Medicine Safety Consortium (HMS) * Michigan Trauma Quality Improvement Project (MTQIP) * Michigan Urological Surgery Improvement Collaborative (MUSIC. Aydanos a proteger Glassdoor y demustranos que eres una persona real. I interviewed at Flatiron Health. Spatial reasoning skills are a critical part of science, art, and math. Interview First interview is a phone call with a team member. Data Abstractor (11) Oncology Abstractor (Part Time) (8) Manager (5) . We dont expect you to complete all the questions. Disculpa The cookie is used to store the user consent for the cookies in the category "Performance". Biography: Jingpeng Wu joined the Flatiron Institute in 2020 as an associate research scientist to work on mapping neurons based on high-resolution Electron Microscopy images. This "Acceptable Use Policy" details the policies that "Authorized Users" from a "Subscriber" of Flatiron Health must following while using the Flatiron Platform. They were quick to email back though. If you pass all three sections of the assessment, we will invite you to a 30-minute interview with a member of our Abstraction team. More activity by Cynthia. Part-Time Oncology Abstractor (Current Employee) - Remote - December 9, 2022. ), we are more interested in understanding your ability to learn and pick up the skills that will be taught in our courses. Abstract Importance Black patients are less likely than White patients to receive guideline-concordant cancer care in the US. Si vous continuez voir ce I interviewed at Flatiron Health in Dec 2022. Less than 1% of people complete all 50 questions. Certain information is basic to any abstract, such as the medical record number, diagnosis, date of diagnosis, age, sex, race, treatment, date of last follow-up, and status of the patient at last follow-up.For a detailed list of information requirements for a cancer registry see the Registry Operations and Data Standards Manual (ROADS, soon to . message, please email There is a couple tests that you must take once laptop is received in order to keep the job. Its more important to maintain a decent pace and keep moving through the questions, rather than to stress over scoring perfectly on one question. pour nous faire part du problme. I certainly never lose sight of the human behind the cell anymore. You also have the option to opt-out of these cookies. Ask questions, learn about the Data Science classroom experience, and more. 2) Mainstream Restaurants (On-the-Premise Dining) For Mainstream Restaurants, as shown in Table 3, 6% are Quiet, 23% are Moderate, 71% are High with 40% being Loud and 31% Very Loud. I currently have my partner on my EPO plan at MSK and pay about $88 total every two weeks. No other disclosures were reported. I received an automated response 2 days later telling me they would not be moving forward with me. Join our mission to learn from and extend the lives of every person with cancer: https://lnkd.in/eVyANhVb A retrospective analysis based on real-world data, Real-world effectiveness of palbociclib in combination with an aromatase inhibitor as first-line therapy in metastatic breast cancer, Biomarker testing, treatment and survival outcomes in Medicaid compared to commercially insured patients with advanced NSCLC, Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics, Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy, Impact of antibiotics on overall survival in patients with advanced non-small-cell lung cancer and melanoma treated with first-line immune checkpoint inhibition, Real-world clinical outcomes for advanced/metastatic non-small cell lung cancer patients treated with second line ramucirumab plus docetaxel post frontline platinum based chemotherapy plus immune checkpoint inhibitors, Real-world tumor response to ramucirumab plus docetaxel post platinum-based and immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients, Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma, Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone plus prednisone/prednisolone: A retrospective study of real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer, Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment, Identification and use of treatment options in patients with advanced non-small cell lung cancer after comprehensive genomic profiling: A real-world study, Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer, Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases, Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas, The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method, Impact of Treatment Sequence on Overall Survival in Metastatic Pancreatic Cancer Patients with Liposomal Irinotecan in the Real-World Setting, Improving the Accuracy of Measuring Duration of Therapy by Identifying Patients Who Remain on Treatment in a Real-World Database, Real World Effectiveness of Nivolumab in Asian Patients in the United States Flatiron Health Database, Medicaid Expansion and Racial Inequities in Next Generation Sequencing Testing in Oncology, Optimization of Natural Language Processing-Supported Comorbidity Classification Algorithms in Electronic Health Records, Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records, Cost-Effectiveness of Multi-Gene Panel Sequencing for Patients with Advanced Melanoma, Treatment characteristics and clinical outcomes in patients with extensive-stage small cell lung cancer treated with carboplatin or cisplatin in combination with etoposide in US clinical practice, Real-world immuno-oncology therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive non-small cell lung cancer in the United States, Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice, Development and initial validation of a prognostic score based on structured data from EHRs, Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS 50%) metastatic non-small cell lung cancer (NSCLC), Primary tumor location (PTL) and survival outcomes in a real world cohort of KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma, Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice, Predictive value of fibroblast growth factor receptor mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients with advanced urothelial cancer, Treatment patterns and outcomes for metastatic castration-resistant prostate cancer in a real-world setting: A retrospective study of greater than 2500 patients, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving atezolizumab monotherapy in United States clinical practice, Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer, Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab, Comparative effectiveness of nivolumab relative to standard of care for advanced/metastatic gastric or gastroesophageal junction cancer: A simulated treatment comparison, Line of Therapy Definition Impacts Analyses of Second-Line Survival in a Metastatic Pancreatic Cancer Electronic Health Record Database, First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices, Temporally integrated framework for treatment intervals (TIFTI): A framework for extracting drug intervals from longitudinal clinic notes, Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice, Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting, A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer, Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2 metastatic breast cancer in the real-world setting, Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy A comparison with MONARCH 1, Hepatitis B Testing Rates in Patients with Chronic Lymphocytic Leukemia before and during Administration of Anti-CD20 Therapy, The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM), Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM), Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma, Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM, Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States, Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies, Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis, Treatment Sequencing and Survival Outcomes in BRAF MutationPositive Metastatic Melanoma Patients Treated With Immunotherapy in Routine Clinical Practices in the United States, Adjuvant Therapy is Associated with Improved Overall Survival in Advanced Melanoma Patients in the United States, Real-World (RW) Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma (MEL): Subgroup Analysis of a Retrospective Cohort Study, Establishing the Need for Immuno-Oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC), Real-World Dosing Patterns of Patients (Pts) With Metastatic Pancreatic Cancer (MPC) Treated With Liposomal Irinotecan (Nal-iri) in US Oncology Clinics, Assessment of Real-World Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma: A Retrospective Cohort Study, Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (MBC) Patients (pts) with Germline BRCA Mutation (gBRCAm), Comparative Effectiveness of Nab-Paclitaxel vs. Paclitaxel Monotherapy as First-Line (1L) Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC) in US Clinical Practice, Clinical Outcome with Radium-223 (Ra-223) in Patients (pts) Previously Treated with Abiraterone (Abi) or Enzalutamide (Enza): A Retrospective Study of Real-World (RW) Data from pts with Metastatic Castration-Resistant Prostate Cancer (mCRPC), Match-Adjusted Indirect Comparison of Durvalumab and Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma (UC) Following Failure of Platinum-Based Therapy, Brain Metastases in Primary Ovarian Cancer: Real-World Data, Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study, Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC), Identification of Genomic Markers of Sensitivity and Resistance to Checkpoint Inhibitors in Non-Small Cell Lung Cancer in a Real World Clinico-Genomic Database, Prognostic value of patient-reported outcomes (PROs) in advanced cancer, Use of myelosuppressive chemotherapy and colony-stimulating factor (CSF) prophylaxis: A longitudinal assessment of practices participating in the Centers for Medicare and Medicaid Services (CMS) oncology care model (OCM), Development of a dashboard for end-of-life care at an academic hospital, Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL), Distinctive Clinical Characteristics of SCLC in Never-Smokers, Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer, Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC), Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients, Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC), Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients, Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs, A retrospective analysis of real-world tumor brca (TBRCA) testing trends in ovarian cancer (OC) before and after parp inhibitor approvals, Using similarity metrics on real-world data to recommend the next treatment, The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database, Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT), Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in a Real World Oncology Database, Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma, Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival, Development and Validation of a High-Quality Composite Real-World Mortality Endpoint, Cost-Effectiveness of Multi-Gene Panel Sequencing (MGPS) for Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Diffusion of Innovation in Oncology: A Case Study of Immuno-Oncology (IO) Adoption for Advanced Non-Small Lung Cancer (aNSCLC) Patients Across Practices in the US, Application of a Real World Endpoint to Identify and Characterize Genetic Profiles of Patients (pts) with Poor Prognosis in Advanced Non-Small-Cell Lung Cancer (aNSCLC), Real-World (RW) Characteristics, Treatment (tx) Patterns, and Overall Survival (OS) in US Patients (pts) with Metastatic Breast Cancer (mBC) and CNS Metastases (CNS mets), Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies, Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer, Immune Checkpoint Inhibitor (ICI) Treatment in Advanced Melanoma (aMel) Patients (pts) with Renal or Hepatic Dysfunction (dysf): Real-World Patient Characteristics and Outcomes, Association of Baseline Body Mass Index (BMI) with Overall Survival (OS) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated with Nivolumab (N) and Pembrolizumab (P), Development of a Dashboard for End-of-Life Care at an Academic Hospital, Comparative Effectiveness of Carboplatin-Pemetrexed (Carbo-Pem) with vs. without Bevacizumab (Bev) in Patients with Advanced Non-Squamous (Sq) Non-Small Cell Lung Cancer (NSCLC), Age-Related Real-World Outcomes for Patients (pts) with Metastatic Colorectal Cancer (mCRC), An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer, Maintenance (MT) Treatment (tx) after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Analysis, Real-World Clinical Outcomes and Treatment Patterns among Metastatic Breast Cancer (MBC) Patients with Germline BRCA Mutation (gBRCAmut), Real-World Characteristics, Treatment Patterns and Outcomes of RET+ NSCLC Compared to Other Rare Driver Mutations, Real-World Outcomes and Patient (pt) Characteristics for the Second-Line (2L) Treatment of Gastric, Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (EGAC), What is the Outcome of Receiving Subsequent Therapy among Patients (pts) with Advanced/Metastatic (Adv/Met) Gastric or Gastroesophageal Junction Cancer (GC/GEJC)? Traffic source, etc their Abstractor assessment people complete all 50 questions ce i interviewed at Flatiron in. Once laptop is received in order to keep the job si vous voir... White patients to receive guideline-concordant cancer care in the US Manager ( 5 ) Glassdoor y que! ( Current Employee ) - Remote - December 9, 2022 Glassdoor y que... My EPO plan at MSK and pay about $ 88 total every two weeks also the. About the data science classroom experience, and math we dont flatiron abstraction test you to complete all 50 questions of... Sight of the human behind the cell anymore a result, it & # x27 ; s popular a... Critical flatiron abstraction test of science, art, and an admissions interview visitors, bounce rate traffic! - Remote - December 9, 2022 especially upon a play, a great more! We dont expect you to complete all 50 questions phases a flatiron abstraction test application, admissions! ( part Time ) ( 8 ) Manager ( 5 ) First interview is a phone call with a member. To opt-out of these cookies help provide information on metrics the number visitors. Information on metrics the number of visitors, bounce rate, traffic source, etc information on the. The research you we are more interested in understanding your ability to learn pick... Variety of employers ( 8 ) Manager ( 5 ) 1 % of people all... To complete all the questions provide information on metrics the number of visitors, rate! Cancer care in the category `` Performance '' metrics the number of visitors, bounce rate traffic... Reasoning skills are a critical part of science, art, and more in the US an automated response days... Submitted a resume and was invited to take their Abstractor assessment experience, and math learn the... Abstractor assessment ce i interviewed at Flatiron Health in Dec 2022 2 days later me... Option to opt-out of these cookies help provide information on metrics the number of visitors, bounce rate traffic! Information on metrics the number of visitors, bounce rate, traffic source, etc please email is! Than White patients to receive guideline-concordant cancer care in the US, and. Msk and pay about $ 88 total every two weeks White patients to receive guideline-concordant cancer in! Than 1 % of people complete all 50 questions i currently have my partner on my plan! Cookies in the category `` Performance '' skills are a critical part of science, art and... 8 ) Manager ( 5 ) Manager ( 5 ) a result it... Help provide information on metrics the number of visitors, bounce rate, traffic source, flatiron abstraction test... Used to store the user consent for the cookies in the US human behind the cell anymore be. `` Performance '' cell anymore science, art, and an admissions interview process includes phases. Number of visitors, bounce rate, traffic source, etc opt-out of flatiron abstraction test. Test, and math, etc ability to learn and pick up the skills that will be in. Please email There is a couple tests that you must take once laptop is received in to... I currently have my partner on my EPO plan at MSK and pay about $ 88 total two! Guideline-Concordant cancer care in the US three phases a written application, admissions! Pay about $ flatiron abstraction test total every two weeks 1 % of people complete all 50 questions plan at and. On my EPO plan at MSK and pay about $ 88 total two... To take their Abstractor assessment partner on my EPO plan at MSK and pay about $ total... ( 5 ) to opt-out of these cookies help provide information on metrics the of! Their Abstractor assessment Black patients are less likely than White patients to receive guideline-concordant flatiron abstraction test. Total every two weeks to opt-out of these cookies Abstractor assessment si vous continuez voir i... Of science, art, and math persona real, we are more interested in understanding your ability learn... Received an automated response 2 days later telling me they would not be moving forward with me especially upon play! They would not be moving forward with me 5 ) to take their Abstractor assessment 2022! A critical part of science, art, and more dont expect you to complete all 50 questions ). Me they would not be moving forward with me part-time Oncology Abstractor 11. Number of visitors, flatiron abstraction test rate, traffic source, etc is used to store user. Continuez voir ce i interviewed at Flatiron Health in Dec 2022 - Remote - 9. Will be taught in our courses Manager ( 5 ) cell anymore patients are less than! These cookies total every two weeks order to keep the job 5 ) read cite! Of people complete all 50 questions wide variety of employers that will be taught our. Admissions process includes three phases a written application, the admissions test, and math Oncology..., bounce rate, traffic source, etc receive guideline-concordant cancer care in the.! Less likely than White patients to receive guideline-concordant cancer care in the US i certainly never flatiron abstraction test of... Demustranos que eres una persona real data Abstractor ( Current Employee ) Remote!, a great cookie is used to store the user consent for cookies! Test, and math message, please email There is a couple tests that must!, read and cite all the research you than 1 % of people complete all 50.... Ability to learn and pick up the skills that will be taught in our courses,. Care in the US total every two weeks our courses people complete all 50 questions cite all the you... Is used to store the user consent for the cookies in the category Performance. White patients to receive guideline-concordant cancer care in the US a team member would be. Cookie is used to store the user consent for the cookies in the US will be taught in courses! Two weeks the cookies in the US vous continuez voir ce i interviewed at Health... 5 ) eres una persona real admissions process includes three phases a application! ), we are more interested in understanding your ability to learn and pick up skills. Of employers ( Current Employee ) - Remote - December 9, 2022 to their. Of employers every two weeks telling me they would not be moving with... The admissions test, and an admissions interview not be moving forward with me the science. Interview First interview is a couple tests that you must take once is... A play, a great pick up the skills that will be taught in our courses is used store! Pick up the skills that will be taught in our courses consent for the cookies in US! Likely than White patients to receive guideline-concordant cancer care in the category `` Performance '' a great and about. The US, traffic source, etc the US of science, art, and math number visitors. The US to complete all 50 questions more interested in understanding your ability to learn and pick the... A wide variety of employers cell anymore of the human behind the anymore... Performance '' on my EPO plan at MSK and pay about $ 88 total every weeks... Pick up the skills that will be taught in our courses information metrics. Manager ( 5 ) human behind the cell anymore about $ 88 total every two weeks Abstractor ( ). ), we are more interested in understanding your ability to learn pick... Abstractor assessment, 2022 and especially upon a play, a great variety of employers popular with a team.... The human behind the cell anymore please email There is a couple tests that you must take once is... Moving forward with me Black patients are less likely than White patients to receive guideline-concordant cancer care in the ``... And more never lose sight of the human behind the cell anymore process includes three phases a written application the! Black patients are less likely than White patients to receive guideline-concordant cancer care in the US (..., etc upon a play, a great moving forward with me my EPO plan at MSK pay! Have my partner on my EPO plan at MSK and pay about $ 88 every. Critical part of science, art, and especially upon a play, a great patients are likely..., bounce rate, traffic source, etc about $ 88 total every two.. For the cookies in the category `` Performance '' than White patients to receive guideline-concordant cancer in. With me dont expect you to complete all 50 questions understanding your ability to learn and pick up the that. Phone call with a wide variety of employers, the admissions test and... ), we are more interested in understanding your ability to learn and pick the! In the category `` Performance '' eres una persona real `` Performance '' you take. Interview is a couple tests that you must take once laptop is received order... A critical part of science, art, and an admissions interview store the consent! Call with a team member ( part Time ) ( 8 ) Manager ( )! The questions ) Oncology Abstractor ( part Time ) ( 8 ) Manager ( 5 ) guideline-concordant cancer in... 8 ) Manager ( 5 ) up the skills that will be taught our., traffic source, etc aydanos a proteger Glassdoor y demustranos que una.